The designation recognizes that Dr. John Langston has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.
NeoTract to Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting
5/16/18: 1 Year Results from the study of UroLift System for the obstructive median lobe twill be presented as a late-breaking abstract.
Data from Large Real-World Study of UroLift® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate
3/19/18: Retrospective Study of Data from More than 800 Patients Consistent with Published, Controlled Clinical Studies.
Treatment for BPH Now “Standard of Care” According to Study Investigators; Results Published in Canadian Journal of Urology NeoTract, Inc., (focused on addressing unmet needs in the field of urology), today announced publication of the five-year results of...
Minimally Invasive Treatment Now Available to Millions More Men Across the United States NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that Cigna, a global health service company...
NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift®
Announced at the American Urological Association 2017 Meeting NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place...
UroLift System for Enlarged Prostate Now Shown to be Durable Through Five Years: Results from Pivotal L.I.F.T. Randomized Study Presented
“The UroLift System is truly a new standard for the treatment of BPH. This conclusion of the landmark L.I.F.T. randomized clinical trial offers high-quality clinical data that demonstrate the durable benefits this unique treatment option can offer,” said Dr. Roehrborn.